Skip to Content

Rule

Change of Names and Addresses; Technical Amendment; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a document that amended its regulations to reflect name and address changes for the Office of Compliance, Center for Drug Evaluation and Research (CDER). The document was published in the Federal Register of August 11, 2004 (69 FR 48774), with incorrect information regarding the mail codes for the Office of Compliance, CDER. This action is editorial in nature and is intended to provide accuracy and clarity to the agency's regulations.

DATES:

This rule is effective August 11, 2004

. Start Further Info

FOR FURTHER INFORMATION CONTACT:

Joyce A Strong, Office of Policy (HF-27), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7010.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA is correcting a document that amended its regulations in 21 CFR part 5 to correct certain mail codes in the Office of Compliance, CDER.

Start List of Subjects

List of Subjects in 21 CFR Part 5

End List of Subjects

Authority delegations (Government agencies), Imports, Organization and functions (Government agencies).

Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs,

End Amendment Part

PART 5—ORGANIZATION

Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 5 U.S.C. 552; 21 U.S.C. 301-397.

End Authority Start Amendment Part

2. Section 5.1100 is amended under the heading “CENTER FOR DRUG EVALUATION AND RESEARCH.

End Amendment Part
Headquarters.

CENTER FOR DRUG EVALUATION AND RESEARCH.1

Office of Compliance.1

Division of New Drugs and Labeling Compliance (HFD-310).

Division of Manufacturing and Product Quality (HFD-320).

Division of Compliance Risk Management and Surveillance (HFD-330).

Start Signature

Dated: August 20, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 04-19598 Filed 8-26-04; 8:45 am]

BILLING CODE 4160-01-S